TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ARS Pharmaceuticals ( (SPRY) ) just unveiled an update.
On November 10, 2025, ARS Pharmaceuticals reported its third-quarter financial results, highlighting $32.5 million in revenue, primarily from U.S. sales of neffy®. The company is actively expanding its market presence with direct-to-consumer campaigns and strategic initiatives to increase prescriber confidence and patient access. Despite a net loss of $51.2 million, ARS Pharmaceuticals maintains a strong cash position to support its operations and growth. The company is also progressing with the global expansion of neffy, having received approval in Japan and launched EURneffy® in the U.K., with further regulatory approvals anticipated in Canada and China. These efforts are expected to enhance ARS Pharmaceuticals’ industry positioning and stakeholder engagement.
The most recent analyst rating on (SPRY) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on ARS Pharmaceuticals stock, see the SPRY Stock Forecast page.
Spark’s Take on SPRY Stock
According to Spark, TipRanks’ AI Analyst, SPRY is a Neutral.
The overall stock score is primarily influenced by strong revenue growth and strategic expansion highlighted in the earnings call. However, the stock’s bearish technical indicators and negative valuation metrics weigh heavily on the score. Financial performance shows potential but is hindered by inconsistent profitability and high investing activities.
To see Spark’s full report on SPRY stock, click here.
More about ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on providing solutions for at-risk patients and their caregivers to manage allergic reactions, particularly anaphylaxis. The company is known for its innovative product, neffy®, an epinephrine nasal spray that is the first needle-free treatment approved by the FDA and the European Commission for Type I allergic reactions.
Average Trading Volume: 2,582,286
Technical Sentiment Signal: Sell
Current Market Cap: $874.6M
See more data about SPRY stock on TipRanks’ Stock Analysis page.